Effect of ticlopidine on coagulation and platelet functions during hemodialysis with cuprophan membranes.
The study is a comparison of two successive HD sessions on each patient. 60 min prior to the first session a placebo was administered orally, while to the second session 500 mg ticlopidine. Arterial blood samples for leucocyte and platelet counts, C3 complement, blood gases, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) measurement were taken before and 15, 30, 60, 120, 240 min during each HD session. Platelet aggregation (ADP 1 microM/ml) was also carried out pre and post-dialysis. It is suggested that ticlopidine: 1) prevents HD-induced complement activation and related phenomena, 2) normalize the increased plasma levels of platelet markers 3) inhibits the ADP-induced platelet aggregation.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D002482:Cellulose / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010978:Platelet Factor 4 / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D013988:Ticlopidine / Q000494:pharmacology*; D001620:beta-Thromboglobulin / Q000378:metabolism
D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D002482:Cellulose; C009865:cuprammonium cellulose; D013988:Ticlopidine